Novocure announced that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma.

“Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few treatment options. We are very pleased Tumor Treating Fields therapy is now available through the Spanish public health system for eligible patients with newly diagnosed glioblastoma,” said Alvaro Nunez, General Manager, Novocure Spain. “The expanded coverage will help more patients benefit from TTFields therapy.”

Patients with newly diagnosed glioblastoma who meet eligibility requirements defined by Spain’s Ministry of Health will be able to access TTFields therapy through hospitals and health centers qualified to offer the treatment.

TTFields are electric fields that disrupt cancer cell division and are administered through a wearable medical device. TTFields therapy received a CE Mark for the treatment of newly diagnosed and recurrent WHO Grade 4 Glioma in adults and is commercially available as a treatment for glioblastoma in multiple countries in North America, Europe and Asia. TTFields therapy is reimbursed in Austria, France, Germany, Israel, Japan, Sweden, Switzerland and the United States. Globally, more than 35,000 patients have been treated with TTFields.